Related Experiment Videos
Mdm2 sensitizes MCF7 breast cancer cells to cisplatin or carboplatin
1Indiana University Cancer Center, Department of Microbiology/Immunology, Indiana University School of Medicine, Indianapolis, USA. marlsmit@iupui.edu
Abstract:
Overexpression of Mdm2 in cancer cells with otherwise wild-type p53 is believed to be an alternative mechanism for p53 inactivation during carcinogenesis. Because a number of genetic alterations that inactivate p53, including mutation, homozygous deletion, or viral oncoprotein expression (e.g. HPV16-E6), inhibit DNA repair, we tested the hypothesis that Mdm2 would likewise inhibit DNA repair. Repair of cisplatin-induced DNA damage was reduced in MCF7 cells overexpressing Mdm2, compared to MCF7 cells in which wild-type p53 function was intact. MCF7-Mdm2 cells exhibited preferential sensitivity to cisplatin and carboplatin. MCF7-Mdm2 cells showed a pronounced S-phase arrest after cisplatin treatment, similar to that observed in mutant-p53 cells in the present and prior studies. MCF7 cells with intact wild-type p53, on the other hand, arrested primarily in G2/M phase after cisplatin treatment. These findings indicate that Mdm2 overexpression can recapitulate the effect of p53 mutations on DNA repair of cisplatin lesions.
Insights
Mdm2 overexpression in cancer cells inhibits DNA repair, similar to p53 mutations. This Mdm2-induced DNA repair defect leads to increased sensitivity to chemotherapy drugs like cisplatin.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- Overexpression of Mdm2 is a potential mechanism for p53 inactivation in cancer.
- Genetic alterations inactivating p53 often impair DNA repair.
- The role of Mdm2 overexpression in DNA repair has not been fully elucidated.
Purpose of the Study:
- To investigate whether Mdm2 overexpression inhibits DNA repair.
- To determine if Mdm2 overexpression affects cancer cell sensitivity to DNA-damaging agents.
- To compare the cellular response to DNA damage in cells with Mdm2 overexpression versus wild-type p53.
Main Methods:
- Utilized MCF7 breast cancer cells with and without Mdm2 overexpression.
- Assessed the repair of cisplatin-induced DNA damage.
- Evaluated cellular sensitivity to cisplatin and carboplatin.
- Analyzed cell cycle progression (S-phase and G2/M arrest) following DNA damage.
Main Results:
- DNA repair of cisplatin-induced damage was reduced in MCF7 cells overexpressing Mdm2 compared to controls.
- MCF7-Mdm2 cells showed increased sensitivity to cisplatin and carboplatin.
- Cisplatin treatment induced a prominent S-phase arrest in MCF7-Mdm2 cells, mimicking mutant-p53 cells.
- Cells with intact wild-type p53 arrested primarily in the G2/M phase after cisplatin treatment.
Conclusions:
- Mdm2 overexpression can inactivate p53's role in DNA repair.
- Mdm2 overexpression recapitulates the DNA repair defects observed in p53-mutated cancer cells.
- This suggests Mdm2 overexpression is a significant factor in chemoresistance and cancer progression.